CY1113164T1 - Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη - Google Patents

Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη

Info

Publication number
CY1113164T1
CY1113164T1 CY20121100910T CY121100910T CY1113164T1 CY 1113164 T1 CY1113164 T1 CY 1113164T1 CY 20121100910 T CY20121100910 T CY 20121100910T CY 121100910 T CY121100910 T CY 121100910T CY 1113164 T1 CY1113164 T1 CY 1113164T1
Authority
CY
Cyprus
Prior art keywords
mannitol
oral
kilostazol
dissulated
powders including
Prior art date
Application number
CY20121100910T
Other languages
English (en)
Inventor
Masafumi Toda
Tadashi Mukai
Original Assignee
Otsuka Pharmaceutical Company Limited.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Company Limited. filed Critical Otsuka Pharmaceutical Company Limited.
Publication of CY1113164T1 publication Critical patent/CY1113164T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει στοματικώς αποσαθρούμενη κόνιν περιλαμβάνουσα κιλοσταζόλη ως δραστικό συστατικό και μαννιτόλη σε ποσότητα 70% κατά βάρος ή και άνω, η οποία μπορεί να ληφθεί χωρίς ύδωρ και η οποία μπορεί να αποσαθρωθεί στη στοματική κοιλότητα. Η εν λόγω κόνις είναι κατάλληλη για ασθενείς στους οποίους χορηγείται κιλοσταζόλη, ειδικά για παρήλικες ασθενείς και ασθενείς πάσχοντες από δυσφαγία.
CY20121100910T 2005-06-29 2012-10-02 Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη CY1113164T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005190156 2005-06-29
EP06780772A EP1901717B1 (en) 2005-06-29 2006-06-28 Orally disintegrating powder comprising cilostazol and mannitol

Publications (1)

Publication Number Publication Date
CY1113164T1 true CY1113164T1 (el) 2016-04-13

Family

ID=37120411

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100910T CY1113164T1 (el) 2005-06-29 2012-10-02 Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη

Country Status (19)

Country Link
US (1) US20090110737A1 (el)
EP (1) EP1901717B1 (el)
JP (1) JP4131747B2 (el)
KR (1) KR101302293B1 (el)
CN (1) CN101212955B (el)
AR (1) AR057413A1 (el)
AU (1) AU2006263068B2 (el)
CA (1) CA2608629C (el)
CY (1) CY1113164T1 (el)
DK (1) DK1901717T3 (el)
ES (1) ES2388613T3 (el)
HK (1) HK1119063A1 (el)
MY (1) MY147888A (el)
PL (1) PL1901717T3 (el)
PT (1) PT1901717E (el)
RU (1) RU2426529C2 (el)
SI (1) SI1901717T1 (el)
TW (1) TWI383809B (el)
WO (1) WO2007001086A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207921A1 (en) 2007-09-14 2017-08-23 Wockhardt Limited Rhein or diacerein compositions
WO2009107864A2 (en) * 2008-02-29 2009-09-03 Otsuka Pharmaceutical Co., Ltd. An orally disintegrating tablet
US20150141517A1 (en) 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR101748215B1 (ko) * 2015-05-29 2017-06-20 한국유나이티드제약 주식회사 경구용 서방성 제제
RU2694233C2 (ru) * 2017-10-13 2019-07-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Средство, обладающее ноотропным воздействием на организм

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029878A (en) * 1975-05-19 1977-06-14 Ici United States Inc. Process for preparing mannitol from glucose
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
EP1203580A4 (en) * 1999-06-18 2004-06-30 Takeda Chemical Industries Ltd SOLID PREPARATIONS WITH FAST DISINTEGRATION
BR0015994A (pt) * 1999-11-30 2002-08-06 Panacea Biotec Ltd Composição de dissolução rápida com sabor doce prolongado
JP2003238393A (ja) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
US20050147666A1 (en) * 2002-03-06 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. Tablets quickly disintegrating in oral cavity
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
BRPI0610780A2 (pt) * 2005-04-22 2016-09-06 Teva Pharma formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete

Also Published As

Publication number Publication date
PT1901717E (pt) 2012-08-07
TW200740469A (en) 2007-11-01
KR101302293B1 (ko) 2013-09-03
CN101212955B (zh) 2012-07-18
RU2008103213A (ru) 2009-08-10
EP1901717B1 (en) 2012-07-18
JP4131747B2 (ja) 2008-08-13
EP1901717A1 (en) 2008-03-26
RU2426529C2 (ru) 2011-08-20
HK1119063A1 (en) 2009-02-27
TWI383809B (zh) 2013-02-01
DK1901717T3 (da) 2012-08-20
JP2008528442A (ja) 2008-07-31
CA2608629A1 (en) 2007-01-04
PL1901717T3 (pl) 2012-12-31
KR20080021158A (ko) 2008-03-06
ES2388613T3 (es) 2012-10-16
WO2007001086A1 (en) 2007-01-04
CA2608629C (en) 2013-11-19
AU2006263068A1 (en) 2007-01-04
AR057413A1 (es) 2007-12-05
SI1901717T1 (sl) 2012-10-30
US20090110737A1 (en) 2009-04-30
MY147888A (en) 2013-01-31
AU2006263068B2 (en) 2011-08-18
CN101212955A (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1114690T1 (el) Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
NO20076687L (no) Oral doseringsform
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
CY1113164T1 (el) Στοματικως αποσαθρουμενη κονις περιλαμβανουσα κιλοσταζολη και μαννιτολη
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE407998T1 (de) Reinigungsmittel
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
RS50611B (sr) "BEZILAT SO 7 - (2- (4- (3 – TRIFLUOROMETIL - FENIL) -1, 2, 3, 6" TETRAHIDRO - PIRID-1- ILI)ETIL)IZOHINOLlNA, NJENO DOBIJANJE I NJENA TERAPEUTSKA PRIMENA
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
ATE399532T1 (de) Medizinische seife
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
SG171472A1 (en) Substituted aniline derivatives
CL2004001272A1 (es) Compuestos derivados de 3-(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-1,1-disustituido-urea; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento del compuesto en el tratamiento de enfermedades relacionadas co
CY1106540T1 (el) Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες